Drozitumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | DR5 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6334H9792N1700O2000S42 |
Molar mass | 143104.43 g·mol−1 |
![]() ![]() |
Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.
Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.[2]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
- ^ a b "Drozitumab". AdisInsight. Retrieved 31 January 2017.